Market revenue in 2023 | USD 21.4 million |
Market revenue in 2030 | USD 37.0 million |
Growth rate | 8.1% (CAGR from 2023 to 2030) |
Largest segment | Diagnostics |
Fastest growing segment | Therapeutics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Diagnostics, Therapeutics |
Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Jubilant Pharmova, Nordion, Bracco, Iren SpA, Abliva AB, Lantheus Holdings Inc, Eckert & Ziegler Bebig SA, Mallinckrodt PLC Ordinary Shares - New, Cardinal Health Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to nuclear medicine market will help companies and investors design strategic landscapes.
Diagnostics was the largest segment with a revenue share of 76.17% in 2023. Horizon Databook has segmented the Israel nuclear medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
Israel is among the five nations in the Middle East that is capable of assembling technetium-99 and molybdenum-99 generators. Israel and Tukey are the only two Middle Eastern countries where alpha emitter-based therapies are available. According to an article published by ScienceDirect, there are nearly 40 nuclear medicine centers, 63 gamma cameras, 26 SPECT/CT systems, 9 PET/CT systems, and 4 cylotrons in Israel.
The reactors have capabilities to produce Carbon-11, as well as perform associated research work. In addition, research work associated with [13N] ammonia is conducted in this country. Therapies using lutetium -177, radium-233, and rhenium-188 are available in Israel. Israel also has a well-developed production and distribution system of radioisotopes.
In early 2018, a Russian-Jewish billionaire provided funds of USD 20 million to an Israeli hospital to conduct research work in nuclear medicine. Furthermore, companies developing new methods for producing radioisotopes is expected to accelerate market growth. For instance, in June 2019, Ben-Gurion University (BGU), a parent company of BGN Technologies Ltd.
Horizon Databook provides a detailed overview of country-level data and insights on the Israel nuclear medicine market , including forecasts for subscribers. This country databook contains high-level insights into Israel nuclear medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account